Efficacy of Regorafenib

Regorafenib (Regorafenib) is a cancer drug that contains the active substance regorafenib, a "protein kinase inhibitor." This means it blocks several enzymes that are important for the tumor's blood supply and the growth and development of cancer cells. It is used alone to treat cancers such as colorectal cancer (cancer of the bowel and rectum) that has spread to other parts of the body; gastrointestinal stromal tumor (GIST, a type of gastrointestinal cancer) that has spread or cannot be removed with surgery; and hepatocellular carcinoma (HCC, a type of liver cancer).

RegofenibIt is used in patients who have received or cannot receive other treatments. For colorectal cancer, these include chemotherapy based on drugs called fluoropyrimidines and treatments with other cancer drugs called anti-VEGF and anti-EGFR therapies. Patients with GIST should try imatinib and sunitinib, and patients with HCC should try sorafenib before starting regorafenib treatment.

RegofenibThe original drug has been launched in China and has entered the scope of Class B medical insurance. Reimbursement is limited to patients who meet the indications. SpecificationThe price of each box of 40mg*28 tablets is around RMB 5,000. The reimbursement ratio is different in different regions, and the price after reimbursement is different. The Turkish version of regorafeniboriginal drug specifications 40mg*28 tablets sold overseas is priced around RMB 6,400 per box (the price may fluctuate due to exchange rates). There are also generic regorafenib drugs produced in other countries, and their drug ingredients are basically the same as those of the original drug. The price of a box of 40mg*90 tablets produced by a Bangladesh pharmaceutical factory is around 2,900 yuan (the price may fluctuate due to exchange rates).